On the other hand, our results showed that GANT61 treatment significantly decreased levels of CD44 in HCC PDOs and cotreatment of sorafenib and that GANT61 inhibited the tumor growth both in vitro and in vivo. This evidence concerns the gene CD44 and hepatocellular carcinoma.